Literature DB >> 30550011

Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin.

Maria Giovanna Danieli1, Chiara Gelardi1, Veronica Pedini1, Armando Gabrielli1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30550011

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


× No keyword cloud information.
  4 in total

1.  Incidence of malignancy in patients with common variable immunodeficiency according to therapeutic delay: an Italian retrospective, monocentric cohort study.

Authors:  Veronica Pedini; Jacopo Umberto Verga; Irene Terrenato; Denise Menghini; Cristina Mezzanotte; Maria Giovanna Danieli
Journal:  Allergy Asthma Clin Immunol       Date:  2020-06-26       Impact factor: 3.406

2.  Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

Authors:  Richard J Jones; Ram K Singh; Fazal Shirazi; Jie Wan; Hua Wang; Xiaobin Wang; Min Jin Ha; Muhamed Baljevic; Isere Kuiatse; Richard E Davis; Robert Z Orlowski
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

3.  Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.

Authors:  Yuru Shang; Xianbin Zhang; Lili Lu; Ke Jiang; Mathias Krohn; Stephanie Matschos; Christina Susanne Mullins; Brigitte Vollmar; Dietmar Zechner; Peng Gong; Michael Linnebacher
Journal:  Br J Cancer       Date:  2021-02-09       Impact factor: 7.640

4.  Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.

Authors:  Maria Giovanna Danieli; Jacopo Umberto Verga; Cristina Mezzanotte; Irene Terrenato; Silvia Svegliati; Maria Beatrice Bilo; Gianluca Moroncini
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.